Fundraise

Honghu Aviation Technology raises ¥70M Series A for cold-chain logistics

What's the deal? Honghu Aviation Technology, a Chinese provider of temperature-controlled logistics solutions, has closed a ¥70M (~$9.6M) Series A round. The investment was led by Chuangjing CapitalDealroom has a profile for this one. Try Dealroom → and Haier CapitalDealroom has a profile for this one. Try Dealroom →.

The company develops both active and passive temperature-control technologies for transporting goods that require strict climate management — pharmaceuticals, vaccines, biological products, raw drug ingredients, and premium fresh food.

Its solutions cover the full range of temperatures, logistics stages, and transport modes, including sea, land, and air freight.

Why now? Global demand for cold-chain logistics has surged in recent years, driven by the expansion of biopharma supply chains and growing consumer expectations for fresh food delivery. China's cold-chain market, in particular, is expanding rapidly as stricter regulations around pharmaceutical transport and food safety raise the bar for compliance.

Haier Capital's involvement signals strategic interest from one of China's largest appliance and smart-home conglomerates, which already has deep ties to refrigeration and cold-chain infrastructure.

What could go wrong? Temperature-controlled logistics is capital-intensive and operationally complex. Honghu faces competition from established players in China's cold-chain market, as well as global logistics giants expanding their capabilities in the region. Scaling across sea, land, and air simultaneously demands heavy investment in equipment, certifications, and partnerships.

The signal: Haier Capital's backing is particularly telling — as an investment arm of the Haier Group, its participation suggests potential strategic integration with one of China's largest cold-chain ecosystems, not just a financial bet. With Honghu still at the early growth stage, this Series A positions it to build out capabilities at a moment when pharma-grade, multi-modal temperature control remains underserved relative to rising regulatory and commercial demand.

Read more: ITjuzi

More top stories